MR-guided biopsy of liver metastases in patients with suspected pancreatic cancer

MR-guided biopsy of liver metastases in patients with suspected pancreatic cancer - META-PANC

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON47537

Enrollment

Registered

2018-08-27

Start date

2019-04-03

Completion date

Unknown

Last updated

2024-04-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver metastases

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age older than 18 years. - Patients with on CECT suspected pancreatic cancer and liver lesions detected by CE-DW-MRI. - Liver lesions cannot be biopsied with transabdominal ultrasound. - Written (signed and dated) informed consent.

Exclusion criteria

Exclusion criteria: - Successful ultrasound-guided liver biopsy with proven metastases. - Insufficient command of the Dutch language to be able to understand the patient information - Pregnancy - Contraindication for MRI

Design outcomes

Primary

Measure	Time frame
Feasibility of MR-guided liver biopsy	—

Secondary

Measure	Time frame
- Percentage representative histopathology of liver lesions. - Procedure duration - Procedure workflow - Occurrence of procedure related complications/adverse events - Lesion size - Skin-to-target length - Histopathologic analysis of metastases. Correlation between different aspects of lesions on MRI and HE-staining. Amount of fibrosis, tumor grade, angiogenesis (MVD). - Optimization of imaging protocol during liver biopsy procedure	—

Measure

Time frame

- Percentage representative histopathology of liver lesions. - Procedure duration - Procedure workflow - Occurrence of procedure related complications/adverse events - Lesion size - Skin-to-target length - Histopathologic analysis of metastases. Correlation between different aspects of lesions on MRI and HE-staining. Amount of fibrosis, tumor grade, angiogenesis (MVD). - Optimization of imaging protocol during liver biopsy procedure

—

Countries

Netherlands

Outcome results